Candriam SCA’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.6M Hold
925,332
0.11% 182
2025
Q4
$19.4M Hold
925,332
0.1% 191
2025
Q3
$14.2M Buy
925,332
+250,247
+37% +$3.28M 0.07% 221
2025
Q2
$6.32M Buy
675,085
+224,650
+50% +$2.47M 0.04% 315
2025
Q1
$5.53M Sell
450,435
-96,730
-18% -$1.36M 0.03% 312
2024
Q4
$7.23M Sell
547,165
-451,454
-45% -$7.73M 0.04% 304
2024
Q3
$19.2M Buy
998,619
+28,513
+3% +$589K 0.11% 184
2024
Q2
$19.9M Sell
970,106
-74,926
-7% -$1.57M 0.12% 169
2024
Q1
$24.9M Buy
1,045,032
+24,000
+2% +$535K 0.16% 139
2023
Q4
$22.1M Buy
1,021,032
+781,022
+325% +$12M 0.15% 151
2023
Q3
$3.48M Hold
240,010
0.02% 357
2023
Q2
$5.02M Sell
240,010
-14,864
-6% -$309K 0.04% 331
2023
Q1
$4.95M Buy
+254,874
New +$6.34M 0.03% 366
2021
Q2
Sell
-25,671
Closed -$548K 936
2021
Q1
$548K Hold
25,671
﹤0.01% 704
2020
Q4
$571K Sell
25,671
-332,701
-93% -$6.9M ﹤0.01% 717
2020
Q3
$5.29M Buy
358,372
+10,914
+3% +$166K 0.05% 347
2020
Q2
$5.15M Buy
+347,458
New +$5.29M 0.05% 325
2018
Q1
Sell
-70,000
Closed -$613K 786
2017
Q4
$613K Buy
+70,000
New +$693K 0.01% 647

Other funds holding SNDX

Candriam SCA's SNDX Position: Q1 2026 in Review

Candriam SCA held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 925,332 shares worth $21.6M. The position accounts for 0.11% of the portfolio, ranked #182.

Candriam SCA first reported a position in SNDX in Q4 2017 and has held it in 18 quarters since. The position peaked at $24.9M in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Candriam SCA held 925,332 shares of Syndax Pharmaceuticals worth $21.6M as of Q1 2026.
  • Candriam SCA left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
  • Syndax Pharmaceuticals made up 0.11% of Candriam SCA's portfolio in Q1 2026, its #182 holding.
  • Candriam SCA first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
  • Candriam SCA's Syndax Pharmaceuticals position peaked at $24.9M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.